Lanzul

Lansoprazole, the active ingredient in Lanzul, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is used to manage conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, erosive esophagitis and to support Helicobacter pylori eradication regimens.

GNH USA supplies Lanzul as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and oncology centres worldwide, ensuring quality and regulatory compliance with a focus on reliable supply chains and product integrity.

Lanzul (lansoprazole) is a proton pump inhibitor that reduces gastric acid secretion, and it is indicated for the following conditions: - Gastro‑oesophageal reflux disease (GERD): relief of heartburn and healing of esophageal erosion. - Peptic ulcer disease: promotes ulcer healing and reduces recurrence. - Erosive esophagitis: heals mucosal damage and prevents further injury. - Helicobacter pylori eradication: used as part of combination therapy to increase eradication rates.

Lanzul may cause adverse reactions, which are categorized as common and serious or rare.

Common Side Effects: - Headache - Diarrhea - Nausea - Abdominal pain - Flatulence - Constipation

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Clostridioides difficile‑associated diarrhea - Low magnesium levels (hypomagnesemia) - Interstitial nephritis

Before prescribing Lanzul, consider the following precautions: - Assess renal function: adjust use in severe renal impairment. - Monitor for liver disease: use cautiously in hepatic impairment. - Avoid long‑term use without supervision: risk of vitamin B12 deficiency. - Consider drug interactions: review concomitant medications. - Pregnancy and lactation: evaluate risk–benefit before use. - Store at room temperature: keep in original container, protect from moisture and light.

Lanzul can interact with other medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption of atazanavir. - Ketoconazole: reduced efficacy of ketoconazole.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR. - Digoxin: may increase serum digoxin levels. - Methotrexate: may increase toxicity.